Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Duffy

Showing results (301-310 of 311) with videos related to

Pageof 32
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Journal of Hepatology|November 7, 2016
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaAustin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, et al.
International Journal of Cancer|May 20, 2016
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancerA G Duffy, O V Makarova-Rusher, S V Ulahannan, et al.
Hepatology (Baltimore, Md.)|December 23, 2018
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract CancerChangqing Xie, Austin G Duffy, Donna Mabry-Hrones, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Journal of the Endocrine Society|November 24, 2022
A Single-Center, Observational Study of 607 Children and Young People Presenting With Differences of Sex Development (DSD)Elim Man, Imran Mushtaq, Angela Barnicoat, et al.
Gut|February 18, 2025
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumabYuta Myojin, Sepideh Babaei, Rajiv Trehan, et al.
Pageof 32

Showing results (301-310 of 311) with videos related to

Sort By:
Pageof 32
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2020
Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 5, 2021
Correction: Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal AdenocarcinomaChangqing Xie, Austin G Duffy, Gagandeep Brar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2017
Phase I and Preliminary Phase II Study of TRC105 in Combination with Sorafenib in Hepatocellular CarcinomaAustin G Duffy, Chi Ma, Susanna V Ulahannan, et al.
Journal for Immunotherapy of Cancer|February 8, 2023
Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancerCecilia Monge, Changqing Xie, Yuta Myojin, et al.
Journal of Hepatology|November 7, 2016
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinomaAustin G Duffy, Susanna V Ulahannan, Oxana Makorova-Rusher, et al.
International Journal of Cancer|May 20, 2016
Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750-an antisense oligonucleotide against eIF4E-in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancerA G Duffy, O V Makarova-Rusher, S V Ulahannan, et al.
Hepatology (Baltimore, Md.)|December 23, 2018
Tremelimumab in Combination With Microwave Ablation in Patients With Refractory Biliary Tract CancerChangqing Xie, Austin G Duffy, Donna Mabry-Hrones, et al.
Journal for Immunotherapy of Cancer|September 14, 2021
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinomaTim F Greten, Ghassan K Abou-Alfa, Ann-Lii Cheng, et al.
Journal of the Endocrine Society|November 24, 2022
A Single-Center, Observational Study of 607 Children and Young People Presenting With Differences of Sex Development (DSD)Elim Man, Imran Mushtaq, Angela Barnicoat, et al.
Gut|February 18, 2025
Multiomics analysis of immune correlatives in hepatocellular carcinoma patients treated with tremelimumab plus durvalumabYuta Myojin, Sepideh Babaei, Rajiv Trehan, et al.
Pageof 32